Brief: Biophytis Requests Pre-Submission Meeting With FDA For Emergency Use Authorization Of Sarconeos For Treatment Of Covid-19
20/07/2023 06:03
July 20 (Reuters) - Biophytis SA ALBPS.PA :
* REQUESTED A PRE-SUBMISSION MEETING WITH THE FDA FOR AN
EMERGENCY USE AUTHORIZATION OF SARCONEOS (BIO101) FOR THE
TREATMENT OF COVID-19
Source text for Eikon: ID:nEQ24yWF3a
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon